Lol! Great paper, & brought to you by biotech & pharma companies: Competing interests: A.J.G. has received travel funding from Alamar Biosciences and is a scientific advisor for Sift Biosciences and BeyondSpring Pharmaceuticals. J.Z. reports grants from Merck, grants and personal fees from Johnson & Johnson and Novartis, personal fees from Bristol Myers Squibb, AstraZeneca, GenePlus, Innovent and Hengrui outside the submitted work. D.L.G. is a scientific advisor for AstraZeneca, Eli Lilly, Menarini Richerche, 4D Pharma, Onconova Therapeutics and Sanofi. P.S. is on the scientific advisory committee for Achelois, Affini-T, Akoya Biosciences, Apricity, Asher Bio, BioAtla LLC, Candel Therapeutics, Catalio, C-Reveal Therapeutics, Dragonfly Therapeutics, Earli Inc, Enable Medicine, Henlius/ Hengenix, Hummingbird, ImaginAb, InterVenn Biosciences, LAVA Therapeutics, Lytix Biopharma, Marker Therapeutics, Matrisome, Oncolytics, Osteologic, PBM Capital, Phenomic AI, Polaris Pharma, Soley Therapeutics, Spotlight, Trained Therapeutix Discovery, Two Bear Capital and Xilis, Inc., and reports private investments in Adaptive Biotechnologies, BioNTech, JSL Health, Sporos and Time Bioventures. S.H.L. receives grant funding from Beyond Spring Pharmaceuticals and Nektar Therapeutics, serves on the scientific advisory boards for Beyond Spring Pharmaceuticals, AstraZeneca and Creatv Microtech, and is co-founder of and holds stock options in Seek Diagnostics. J.V.H. reports being on advisory committees for BioNTech, Genentech, Mirati Therapeutics, Eli Lilly, Janssen, Boehringer Ingelheim, Regeneron, Takeda, BerGenBio, Jazz, Curio Science, Novartis, AstraZeneca, BioAlta, Sanofi, Spectrum, GlaxoSmithKline, EMD Serono, BluePrint Medicine and Chugai; support from AstraZeneca, Boehringer Ingelheim, Spectrum, Mirati, Bristol Myers Squibb and Takeda; and licensing or royalties from Spectrum. E.J.S. is a paid consultant for Siren Biotechnology, an external advisory board member at Nature’s Toolbox (NTX) with stock options, and a scientific advisor for iOncologi, Inc. The Article discusses patented technologies related to RNA therapeutics from A.J.G., C.M., S.H.L, D.S., H.R.M.-G. and E.J.S. Some of these technologies are licensed or under option to license by iOncologi, Inc. H.R.M.-G. and E.J.S. receive royalty payments from patents licensed to iOncologi. The other authors declare no competing interests.

7. Eli Lilly, Janssen, Boehringer Ingelheim, Regeneron, Takeda, BerGenBio, Jazz, Curio Science, Novartis, AstraZeneca, BioAlta, Sanofi, Spectrum, GlaxoSmithKline, EMD Serono, BluePrint Medicine and Chugai; support from AstraZeneca, Boehringer Ingelheim, Spectrum ...

“Ethics declarations Competing interests A.J.G. has received travel funding from Alamar Biosciences and is a scientific advisor for Sift Biosciences and BeyondSpring Pharmaceuticals. J.Z. reports grants from Merck, grants and personal fees from Johnson & Johnson and Novartis, personal fees from Bristol Myers Squibb, AstraZeneca, GenePlus, Innovent and Hengrui outside the submitted work. D.L.G. is a scientific advisor for AstraZeneca, Eli Lilly, Menarini Richerche, 4D Pharma, Onconova Therapeutics and Sanofi. P.S. is on the scientific advisory committee for Achelois, Affini-T, Akoya Biosciences, Apricity, Asher Bio, BioAtla LLC, Candel Therapeutics, Catalio, C-Reveal Therapeutics, Dragonfly Therapeutics, Earli Inc, Enable Medicine, Henlius/Hengenix, Hummingbird, ImaginAb, InterVenn Biosciences, LAVA Therapeutics, Lytix Biopharma, Marker Therapeutics, Matrisome, Oncolytics, Osteologic, PBM Capital, Phenomic AI, Polaris Pharma, Soley Therapeutics, Spotlight, Trained Therapeutix Discovery, Two Bear Capital and Xilis, Inc., and reports private investments in Adaptive Biotechnologies, BioNTech, JSL Health, Sporos and Time Bioventures. S.H.L. receives grant funding from Beyond Spring Pharmaceuticals and Nektar Therapeutics, serves on the scientific advisory boards for Beyond Spring Pharmaceuticals, AstraZeneca and Creatv Microtech, and is co-founder of and holds stock options in Seek Diagnostics. J.V.H. reports being on advisory committees for BioNTech, Genentech, Mirati Therapeutics, Eli Lilly, Janssen, Boehringer Ingelheim, Regeneron, Takeda, BerGenBio, Jazz, Curio Science, Novartis, AstraZeneca, BioAlta, Sanofi, Spectrum, GlaxoSmithKline, EMD Serono, BluePrint Medicine and Chugai; support from AstraZeneca, Boehringer Ingelheim, Spectrum, Mirati, Bristol Myers Squibb and Takeda; and licensing or royalties from Spectrum. E.J.S. is a paid consultant for Siren Biotechnology, an external advisory board member at Nature’s Toolbox (NTX) with stock options, and a scientific advisor for iOncologi, Inc. The Article discusses patented technologies related to RNA therapeutics from A.J.G., C.M., S.H.L, D.S., H.R.M.-G. and E.J.S. Some of these technologies are licensed or under option to license by iOncologi, Inc. H.R.M.-G. and E.J.S. receive royalty payments from patents licensed to iOncologi. The other authors declare no competing interests.”

C0v!d taught us to beware of industry funded studies. The COIs are eye-watering! 👇 "Competing interests A.J.G. has received travel funding from Alamar Biosciences and is a scientific advisor for Sift Biosciences and BeyondSpring Pharmaceuticals. J.Z. reports grants from Merck, grants and personal fees from Johnson & Johnson and Novartis, personal fees from Bristol Myers Squibb, AstraZeneca, GenePlus, Innovent and Hengrui outside the submitted work. D.L.G. is a scientific advisor for AstraZeneca, Eli Lilly, Menarini Richerche, 4D Pharma, Onconova Therapeutics and Sanofi. P.S. is on the scientific advisory committee for Achelois, Affini-T, Akoya Biosciences, Apricity, Asher Bio, BioAtla LLC, Candel Therapeutics, Catalio, C-Reveal Therapeutics, Dragonfly Therapeutics, Earli Inc, Enable Medicine, Henlius/ Hengenix, Hummingbird, ImaginAb, InterVenn Biosciences, LAVA Therapeutics, Lytix Biopharma, Marker Therapeutics, Matrisome, Oncolytics, Osteologic, PBM Capital, Phenomic AI, Polaris Pharma, Soley Therapeutics, Spotlight, Trained Therapeutix Discovery, Two Bear Capital and Xilis, Inc., and reports private investments in Adaptive Biotechnologies, BioNTech, JSL Health, Sporos and Time Bioventures. S.H.L. receives grant funding from Beyond Spring Pharmaceuticals and Nektar Therapeutics, serves on the scientific advisory boards for Beyond Spring Pharmaceuticals, AstraZeneca and Creatv Microtech, and is co-founder of and holds stock options in Seek Diagnostics. J.V.H. reports being on advisory committees for BioNTech, Genentech, Mirati Therapeutics, Eli Lilly, Janssen, Boehringer Ingelheim, Regeneron, Takeda, BerGenBio, Jazz, Curio Science, Novartis, AstraZeneca, BioAlta, Sanofi, Spectrum, GlaxoSmithKline, EMD Serono, BluePrint Medicine and Chugai; support from AstraZeneca, Boehringer Ingelheim, Spectrum, Mirati, Bristol Myers Squibb and Takeda; and licensing or royalties from Spectrum. E.J.S. is a paid consultant for Siren Biotechnology, an external advisory board member at Nature’s Toolbox (NTX) with stock options, and a scientific advisor for iOncologi, Inc. The Article discusses patented technologies related to RNA therapeutics from A.J.G., C.M., S.H.L, D.S., H.R.M.-G. and E.J.S. Some of these technologies are licensed or under option to license by iOncologi, Inc. H.R.M.-G. and E.J.S. receive royalty payments from patents licensed to iOncologi. The other authors declare no competing interests."

Beware of funding COIs when evaluating papers. Some results 👇may be bought & paid for. C0v!d taught us that. nature.com/articles/s41586-0… Competing interests A.J.G. has received travel funding from Alamar Biosciences and is a scientific advisor for Sift Biosciences and BeyondSpring Pharmaceuticals. J.Z. reports grants from Merck, grants and personal fees from Johnson & Johnson and Novartis, personal fees from Bristol Myers Squibb, AstraZeneca, GenePlus, Innovent and Hengrui outside the submitted work. D.L.G. is a scientific advisor for AstraZeneca, Eli Lilly, Menarini Richerche, 4D Pharma, Onconova Therapeutics and Sanofi. P.S. is on the scientific advisory committee for Achelois, Affini-T, Akoya Biosciences, Apricity, Asher Bio, BioAtla LLC, Candel Therapeutics, Catalio, C-Reveal Therapeutics, Dragonfly Therapeutics, Earli Inc, Enable Medicine, Henlius/ Hengenix, Hummingbird, ImaginAb, InterVenn Biosciences, LAVA Therapeutics, Lytix Biopharma, Marker Therapeutics, Matrisome, Oncolytics, Osteologic, PBM Capital, Phenomic AI, Polaris Pharma, Soley Therapeutics, Spotlight, Trained Therapeutix Discovery, Two Bear Capital and Xilis, Inc., and reports private investments in Adaptive Biotechnologies, BioNTech, JSL Health, Sporos and Time Bioventures. S.H.L. receives grant funding from Beyond Spring Pharmaceuticals and Nektar Therapeutics, serves on the scientific advisory boards for Beyond Spring Pharmaceuticals, AstraZeneca and Creatv Microtech, and is co-founder of and holds stock options in Seek Diagnostics. J.V.H. reports being on advisory committees for BioNTech, Genentech, Mirati Therapeutics, Eli Lilly, Janssen, Boehringer Ingelheim, Regeneron, Takeda, BerGenBio, Jazz, Curio Science, Novartis, AstraZeneca, BioAlta, Sanofi, Spectrum, GlaxoSmithKline, EMD Serono, BluePrint Medicine and Chugai; support from AstraZeneca, Boehringer Ingelheim, Spectrum, Mirati, Bristol Myers Squibb and Takeda; and licensing or royalties from Spectrum. E.J.S. is a paid consultant for Siren Biotechnology, an external advisory board member at Nature’s Toolbox (NTX) with stock options, and a scientific advisor for iOncologi, Inc. The Article discusses patented technologies related to RNA therapeutics from A.J.G., C.M., S.H.L, D.S., H.R.M.-G. and E.J.S. Some of these technologies are licensed or under option to license by iOncologi, Inc. H.R.M.-G. and E.J.S. receive royalty payments from patents licensed to iOncologi. The other authors declare no competing interests.

🔄 Bergenbio Oncoinvent Merge: Pivoting from Failed Lung Cancer to Radiopharma Promise 🚀 🧪 Bemcentinib scrapped, Bergenbio taps out—now merging into Oncoinvent, a clinical-stage Radspherin® radiopharma player 💸 Fully underwritten NOK 130M rights issue ensures funding through 2027 for Phase 2 ovarian cancer trials 📊 Ownership split: Oncoinvent 75%, Bergenbio 25%; Oncoinvent maintains name and leadership 📈 Strategy refocus: Access to Oslo Børs main list, stronger investor appeal, and financial lifeline 🎯 Signals a hard pivot—from lung cancer disappointment to ovarian/cancer radiotherapy—and a reset in Norwegian biotech strategy This merger shows the tough choices small biotechs face after clinical setbacks—and how strategic consolidation in novel modalities like radiopharma can offer new paths to survival and clinical progress. #Bergenbio #Oncoinvent #Radiopharma #Radspherin #BiotechMerge #CancerTherapy #OvarianCancer #Phase2 #BiotechStrategy #Funding2027

Er Bergenbio den mest solide og bærekraftige aksjen på Oslo børs?

Hvis du trodde twitter har blitt ille. Da har du ikke fått med deg Nordnet kommentarfeltet på Bergenbio aksjen. Sitat fra anonym "Kreftforskning er den virkelige kreften"

BerGenBio bins lung cancer asset, mulls strategic options $BGBIO firstwordpharma.com/story/59…

Well... no more luck in STK11m, dud again $BGBIO The comedy already lasted for way too long. BerGenBio announces discontinuation of 1L STK11M NSCLC study and exploration of strategic alternatives mfn.se/cis/a/bergenbio/berge…

BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients: Ph1b data support safety, predictable PK and adequate plasma exposure BERGEN, Norway, Oct. 7, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage… dlvr.it/TF40vp

Vi ser at det er en to nye aksjer på short listen siden forrige mandag: Bergenbio med en shortandel på 0,66% og Mowi med en shortandel på 0,51%. investornytt.no/oslo-bors-sh…

Update #Lungcancer #oncology #cancer #genomics #precisionmedicine BerGenBio Partners with Tempus to Advance Development in STK11-Mutant Non-Small Cell Lung Cancer (nextedge.in)

@Coolbreez016 god lesing om info om bergenbio! biotuesdays.com/2024/07/16/b…

BerGenBio is developing a pipeline of transformative drugs targeting AXL as a cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections $BGBIO biotuesdays.com/2024/07/16/b…

BergenBio har jeg ikke, men kommer en kort en på Norse :) Har tapt for mye penger på BergenBio i gamledagene, men må mulig begynne å se på den igjen

Ser de skriver at T. Mohn har stortkjøpt i BergenBio. Er vel samme feilen…

BerGenBio enters clinical trial collaboration with UT Health San Antonio and Sobi pharmabiz.com/NewsDetails.as… Published by pharmabiz.com

‘’Comparison is the thief of joy’’ Skal sies at de siste 3 månedene for meg har gått veldig sideveis. Bestemte meg for å holde på Bergenbio. Er nå -10%, var 70% i pluss. Lang horisont, så tenker ikke noe særlig over det. Er 3 aksjer jeg har holdt en stund emgs, bgbio og eam.